vs
Side-by-side financial comparison of BRC Group Holdings, Inc. (RILY) and Bio-Techne (TECH). Click either name above to swap in a different company.
Bio-Techne is the larger business by last-quarter revenue ($295.9M vs $188.3M, roughly 1.6× BRC Group Holdings, Inc.). BRC Group Holdings, Inc. runs the higher net margin — 47.9% vs 12.8%, a 35.1% gap on every dollar of revenue. On growth, Bio-Techne posted the faster year-over-year revenue change (-6.4% vs -21.9%). Over the past eight quarters, Bio-Techne's revenue compounded faster (4.2% CAGR vs -15.4%).
Bio-Techne Corporation is an American life sciences company that develops, manufactures and sells life science reagents, instruments and services for the research, diagnostic, and bioprocessing markets.
RILY vs TECH — Head-to-Head
Income Statement — Q4 FY2025 vs Q2 FY2026
| Metric | | |
|---|---|---|
| Revenue | $188.3M | $295.9M |
| Net Profit | $90.3M | $38.0M |
| Gross Margin | 79.5% | 64.6% |
| Operating Margin | 32.3% | 18.4% |
| Net Margin | 47.9% | 12.8% |
| Revenue YoY | -21.9% | -6.4% |
| Net Profit YoY | 1710.8% | 68.3% |
| EPS (diluted) | $2.78 | $0.24 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $188.3M | $295.9M | ||
| Q3 25 | $215.3M | — | ||
| Q2 25 | $188.2M | $317.0M | ||
| Q1 25 | $197.2M | $316.2M | ||
| Q4 24 | $241.0M | $297.0M | ||
| Q3 24 | $225.5M | $289.5M | ||
| Q2 24 | $256.0M | $306.1M | ||
| Q1 24 | $263.4M | $303.4M |
| Q4 25 | $90.3M | $38.0M | ||
| Q3 25 | $91.1M | — | ||
| Q2 25 | $139.5M | $-17.7M | ||
| Q1 25 | $-10.0M | $22.6M | ||
| Q4 24 | $-5.6M | $34.9M | ||
| Q3 24 | $-284.4M | $33.6M | ||
| Q2 24 | $-433.6M | $40.6M | ||
| Q1 24 | $-49.2M | $49.1M |
| Q4 25 | 79.5% | 64.6% | ||
| Q3 25 | 83.7% | — | ||
| Q2 25 | 81.3% | 62.7% | ||
| Q1 25 | 81.4% | 67.9% | ||
| Q4 24 | 79.8% | 65.3% | ||
| Q3 24 | 82.1% | 63.2% | ||
| Q2 24 | 84.5% | 66.4% | ||
| Q1 24 | 85.3% | 67.4% |
| Q4 25 | 32.3% | 18.4% | ||
| Q3 25 | 30.4% | — | ||
| Q2 25 | 5.7% | -7.5% | ||
| Q1 25 | -31.2% | 12.2% | ||
| Q4 24 | -69.2% | 16.0% | ||
| Q3 24 | -36.4% | 13.8% | ||
| Q2 24 | -90.8% | 15.0% | ||
| Q1 24 | -6.1% | 22.1% |
| Q4 25 | 47.9% | 12.8% | ||
| Q3 25 | 42.3% | — | ||
| Q2 25 | 74.1% | -5.6% | ||
| Q1 25 | -5.1% | 7.1% | ||
| Q4 24 | -2.3% | 11.7% | ||
| Q3 24 | -126.1% | 11.6% | ||
| Q2 24 | -169.4% | 13.3% | ||
| Q1 24 | -18.7% | 16.2% |
| Q4 25 | $2.78 | $0.24 | ||
| Q3 25 | $2.91 | — | ||
| Q2 25 | $4.50 | $-0.11 | ||
| Q1 25 | $-0.39 | $0.14 | ||
| Q4 24 | $-0.01 | $0.22 | ||
| Q3 24 | $-9.39 | $0.21 | ||
| Q2 24 | $-14.35 | $0.26 | ||
| Q1 24 | $-1.71 | $0.31 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $226.6M | $172.9M |
| Total DebtLower is stronger | $1.4B | $260.0M |
| Stockholders' EquityBook value | $-171.5M | $2.0B |
| Total Assets | $1.7B | $2.5B |
| Debt / EquityLower = less leverage | — | 0.13× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $226.6M | $172.9M | ||
| Q3 25 | $184.2M | — | ||
| Q2 25 | $267.4M | $162.2M | ||
| Q1 25 | $138.3M | $140.7M | ||
| Q4 24 | $146.9M | $177.5M | ||
| Q3 24 | $159.2M | $187.5M | ||
| Q2 24 | $236.9M | $152.9M | ||
| Q1 24 | $190.7M | $145.3M |
| Q4 25 | $1.4B | $260.0M | ||
| Q3 25 | $1.3B | — | ||
| Q2 25 | $1.3B | $346.0M | ||
| Q1 25 | $1.4B | $330.0M | ||
| Q4 24 | $1.5B | $300.0M | ||
| Q3 24 | — | $300.0M | ||
| Q2 24 | — | $319.0M | ||
| Q1 24 | — | $389.0M |
| Q4 25 | $-171.5M | $2.0B | ||
| Q3 25 | $-260.5M | — | ||
| Q2 25 | $-351.7M | $1.9B | ||
| Q1 25 | $-496.8M | $2.0B | ||
| Q4 24 | $-488.2M | $2.1B | ||
| Q3 24 | $-497.6M | $2.1B | ||
| Q2 24 | $-218.3M | $2.1B | ||
| Q1 24 | $228.4M | $2.0B |
| Q4 25 | $1.7B | $2.5B | ||
| Q3 25 | $1.7B | — | ||
| Q2 25 | $1.5B | $2.6B | ||
| Q1 25 | $1.5B | $2.6B | ||
| Q4 24 | $1.8B | $2.7B | ||
| Q3 24 | $2.2B | $2.7B | ||
| Q2 24 | $3.2B | $2.7B | ||
| Q1 24 | $5.0B | $2.7B |
| Q4 25 | — | 0.13× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 0.18× | ||
| Q1 25 | — | 0.16× | ||
| Q4 24 | — | 0.14× | ||
| Q3 24 | — | 0.14× | ||
| Q2 24 | — | 0.15× | ||
| Q1 24 | — | 0.19× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $26.2M | — |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | 0.29× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $26.2M | — | ||
| Q3 25 | $-60.6M | — | ||
| Q2 25 | $-25.6M | $98.2M | ||
| Q1 25 | $184.0K | $41.1M | ||
| Q4 24 | $-2.7M | $84.3M | ||
| Q3 24 | $19.5M | $63.9M | ||
| Q2 24 | $111.5M | $75.5M | ||
| Q1 24 | $135.4M | $81.0M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | $93.3M | ||
| Q1 25 | — | $31.0M | ||
| Q4 24 | — | $77.5M | ||
| Q3 24 | — | $54.7M | ||
| Q2 24 | — | $57.5M | ||
| Q1 24 | — | $64.5M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 29.4% | ||
| Q1 25 | — | 9.8% | ||
| Q4 24 | — | 26.1% | ||
| Q3 24 | — | 18.9% | ||
| Q2 24 | — | 18.8% | ||
| Q1 24 | — | 21.3% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 1.5% | ||
| Q1 25 | — | 3.2% | ||
| Q4 24 | — | 2.3% | ||
| Q3 24 | — | 3.2% | ||
| Q2 24 | — | 5.9% | ||
| Q1 24 | — | 5.4% |
| Q4 25 | 0.29× | — | ||
| Q3 25 | -0.66× | — | ||
| Q2 25 | -0.18× | — | ||
| Q1 25 | — | 1.82× | ||
| Q4 24 | — | 2.42× | ||
| Q3 24 | — | 1.90× | ||
| Q2 24 | — | 1.86× | ||
| Q1 24 | — | 1.65× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
RILY
| Transferred At Point In Time | $101.4M | 54% |
| Wealth Management Segment | $30.7M | 16% |
| Corporate Finance Consulting And Investment Banking Fees | $27.1M | 14% |
| Services And Fees | $24.8M | 13% |
| Commissions Fees And Reimbursed Expenses | $4.8M | 3% |
TECH
| Diagnostics And Spatial Biology | $81.2M | 27% |
| EMEA Excluding UK | $75.4M | 25% |
| Other | $42.4M | 14% |
| Instruments | $29.6M | 10% |
| APAC Excluding Greater China | $22.7M | 8% |
| Services | $22.3M | 8% |
| GB | $13.7M | 5% |
| Royalty | $8.5M | 3% |
